Assessing the potential for in vivo modulation of <i>FTH1 gene</i> expression with small peptides to restore and enhance androgen receptor pathway inhibition in prostate cancer.

Cancer Biol Ther · 2025 · PMC12068333 · PMID 40340699

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While the mean tumor volume was nearly 30% lower on day 49 with the combination treatment of bicalutamide and FT-002, this difference compared to the control did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Assessing the potential for in vivo modulation of &lt;i&gt;FTH1 gene&lt;/i&gt; expression with small peptides to restore and enhance androgen receptor pathway inhibition in prostate cancer.

The sentences

Assessing the potential for in vivo modulation of <i>FTH1 gene</i> expression with small peptides to restore and enhance androgen receptor pathway inhibition in prostate cancer.